BIOGEN INC. Equity Securities, FV-NI, Gain (Loss)
BIOGEN INC. (BIIB) reported Equity Securities, FV-NI, Gain (Loss) of -$22.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-04-29
- BIOGEN INC. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was -$22.30M, a 162.64% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$14.40M, a 118.34% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $3.80M.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was -$5.30M, a 117.43% decline year-over-year.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for fiscal 2025 was $19.70M, a 80.38% decline from fiscal 2024.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was $100.40M, a 63.52% decline from fiscal 2023.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was $275.20M, a 3.97% increase from fiscal 2022.
- BIOGEN INC. equity securities, fv-ni, gain (loss) for fiscal 2022 was $264.70M, a 67.76% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Gain (Loss) 12 month | Equity Securities, FV-NI, Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$22.30M 10-Q · filed 2026-04-29 | -$36.70M derived: sum of 2 quarters · filed 2026-04-29 | -$32.90M derived: sum of 3 quarters · filed 2026-04-29 | -$38.20M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-12-31 | -$14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | -$10.60M derived: sum of 2 quarters · filed 2026-02-06 | -$15.90M derived: sum of 3 quarters · filed 2026-02-06 | $19.70M 10-K · filed 2026-02-06 | ||||
| 2025-09-30 | $3.80M 10-Q · filed 2025-10-30 | -$1.50M derived: sum of 2 quarters · filed 2025-10-30 | $34.10M 10-Q · filed 2025-10-30 | $112.60M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-06-30 | -$5.30M 10-Q · filed 2025-07-31 | $30.30M 10-Q · filed 2025-07-31 | $108.80M derived: sum of 3 quarters · filed 2026-04-29 | $69.70M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-03-31 | $35.60M 10-Q · filed 2026-04-29 | $114.10M derived: sum of 2 quarters · filed 2026-04-29 | $75.00M derived: sum of 3 quarters · filed 2026-04-29 | $105.40M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $78.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $39.40M derived: sum of 2 quarters · filed 2026-02-06 | $69.80M derived: sum of 3 quarters · filed 2026-02-06 | $100.40M 10-K · filed 2026-02-06 | ||||
| 2024-09-30 | -$39.10M 10-Q · filed 2025-10-30 | -$8.70M derived: sum of 2 quarters · filed 2025-10-30 | $21.90M 10-Q · filed 2025-10-30 | $23.50M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2024-06-30 | $30.40M 10-Q · filed 2025-07-31 | $61.00M 10-Q · filed 2025-07-31 | $62.60M derived: sum of 3 quarters · filed 2026-02-06 | $364.60M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2024-03-31 | $30.60M 10-Q · filed 2025-05-01 | $32.20M derived: sum of 2 quarters · filed 2026-02-06 | $334.20M derived: sum of 3 quarters · filed 2026-02-06 | $227.70M derived: sum of 4 quarters · filed 2026-02-06 | ||||
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $303.60M derived: sum of 2 quarters · filed 2026-02-06 | $197.10M derived: sum of 3 quarters · filed 2026-02-06 | $275.20M 10-K · filed 2026-02-06 | ||||
| 2023-09-30 | $302.00M 10-Q · filed 2024-10-30 | $195.50M derived: sum of 2 quarters · filed 2024-10-30 | $273.60M 10-Q · filed 2024-10-30 | $380.20M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | -$106.50M 10-Q · filed 2024-08-01 | -$28.40M 10-Q · filed 2024-08-01 | $78.20M derived: sum of 3 quarters · filed 2025-02-12 | -$31.60M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $78.10M 10-Q · filed 2024-04-24 | $184.70M derived: sum of 2 quarters · filed 2025-02-12 | $74.90M derived: sum of 3 quarters · filed 2025-02-12 | $152.10M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $106.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$3.20M derived: sum of 2 quarters · filed 2025-02-12 | $74.00M derived: sum of 3 quarters · filed 2025-02-12 | $264.70M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | -$109.80M 10-Q · filed 2023-11-08 | -$32.60M derived: sum of 2 quarters · filed 2023-11-08 | $158.10M 10-Q · filed 2023-11-08 | $273.30M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-06-30 | $77.20M 10-Q · filed 2023-07-25 | -$77.20M 10-Q · filed 2022-07-20 | $267.90M 10-Q · filed 2023-07-25 | -$267.90M 10-Q · filed 2022-07-20 | $383.10M derived: sum of 3 quarters · filed 2024-02-14 | $807.30M derived: sum of 4 quarters · filed 2024-02-14 | ||
| 2022-03-31 | $190.70M 10-Q · filed 2023-04-25 | -$190.70M 10-Q · filed 2022-05-03 | $305.90M derived: sum of 2 quarters · filed 2024-02-14 | $730.10M derived: sum of 3 quarters · filed 2024-02-14 | $884.40M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2021-12-31 | $115.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $539.40M derived: sum of 2 quarters · filed 2024-02-14 | $693.70M derived: sum of 3 quarters · filed 2024-02-14 | $821.10M 10-K · filed 2024-02-14 | -$821.10M 10-K · filed 2022-02-03 | |||
| 2021-09-30 | $424.20M 10-Q · filed 2022-10-25 | -$424.20M 10-Q · filed 2021-10-20 | $578.50M derived: sum of 2 quarters · filed 2022-10-25 | $705.90M 10-Q · filed 2022-10-25 | -$705.90M 10-Q · filed 2021-10-20 | -$511.20M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-06-30 | $154.30M 10-Q · filed 2022-07-20 | -$281.80M 10-Q · filed 2022-07-20 | -$935.40M derived: sum of 3 quarters · filed 2023-02-15 | -$1.02B derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | -$436.10M 10-Q · filed 2022-05-03 | -$1.09B derived: sum of 2 quarters · filed 2023-02-15 | -$1.17B derived: sum of 3 quarters · filed 2023-02-15 | -$1.07B derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$653.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$735.90M derived: sum of 2 quarters · filed 2023-02-15 | -$633.00M derived: sum of 3 quarters · filed 2023-02-15 | -$693.90M 10-K · filed 2023-02-15 | $693.90M 10-K · filed 2021-02-03 | |||
| 2020-09-30 | -$82.30M 10-Q · filed 2021-10-20 | $20.60M derived: sum of 2 quarters · filed 2021-10-20 | -$40.30M 10-Q · filed 2021-10-20 | -$37.50M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | $102.90M 10-Q · filed 2021-07-22 | $42.00M 10-Q · filed 2021-07-22 | $44.80M derived: sum of 3 quarters · filed 2022-02-03 | $40.20M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-03-31 | -$60.90M 10-Q · filed 2021-04-22 | -$58.10M derived: sum of 2 quarters · filed 2022-02-03 | -$62.70M derived: sum of 3 quarters · filed 2022-02-03 | -$236.90M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$1.80M derived: sum of 2 quarters · filed 2022-02-03 | -$176.00M derived: sum of 3 quarters · filed 2022-02-03 | $200.10M 10-K · filed 2022-02-03 | ||||
| 2019-09-30 | -$4.60M 10-Q · filed 2020-10-21 | -$178.80M derived: sum of 2 quarters · filed 2020-10-21 | $197.30M 10-Q · filed 2020-10-21 | $184.70M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-06-30 | -$174.20M 10-Q · filed 2020-07-22 | $201.90M 10-Q · filed 2020-07-22 | $189.30M derived: sum of 3 quarters · filed 2021-02-03 | $330.50M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-03-31 | $375.30M 10-Q · filed 2020-04-23 | $363.50M derived: sum of 2 quarters · filed 2021-02-03 | $504.70M derived: sum of 3 quarters · filed 2021-02-03 | $510.10M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2018-12-31 | -$11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $129.40M derived: sum of 2 quarters · filed 2021-02-03 | $134.80M derived: sum of 3 quarters · filed 2021-02-03 | $127.90M 10-K · filed 2021-02-03 | ||||
| 2018-09-30 | $141.20M 10-Q · filed 2019-10-22 | $146.60M derived: sum of 2 quarters · filed 2019-10-22 | $139.70M 10-Q · filed 2019-10-22 | |||||
| 2018-06-30 | $5.40M 10-Q · filed 2019-07-24 | -$1.50M 10-Q · filed 2019-07-24 | ||||||
| 2017-12-31 | -$19.80M 10-K · filed 2020-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |